Author

Jodi Virkus

Observed name: J. Virkus

Institution: Novartis (United States)

Observed institution: Novartis (United States)

OpenAlex ID: A5086975414

Iron Chelation with Deferasirox (Exjade®) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS)

2008 · Alan F List, Maria R Baer, et al. · Blood · 31

Deferasirox (ICL670; Exjade®) Reduces Serum Ferritin (SF) and Labile Plasma Iron (LPI) in Patients with Myelodysplastic Syndromes (MDS).

2007 · Alan F. List, M.R. Baer, et al. · Blood · 24

Deferasirox (Exjade®) Monotherapy Significantly Reduces Cardiac Iron Burden in Chronically Transfused β-Thalassemia Patients: An MRI T2* Study

2008 · John C Wood, Alexis A. Thompson, et al. · Blood · 13

Exjade® Reduces Cardiac Iron Burden in Chronically Transfused β-Thalassemia Patients: An MRI T2* Study.

2007 · J. Wood, A.A. Thompson, et al. · Blood · 5

Works count: 4

Citation count: 73

H-index: 4

I10-index: 3